Research ArticleBone

ATRAID regulates the action of nitrogen-containing bisphosphonates on bone

See allHide authors and affiliations

Science Translational Medicine  20 May 2020:
Vol. 12, Issue 544, eaav9166
DOI: 10.1126/scitranslmed.aav9166

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Screening for side effect susceptibility

Osteoporosis is typically treated with nitrogen-containing bisphosphonates (N-BPs), which inhibit bone resorption; however, N-BPs can cause serious side effects including osteonecrosis of the jaw and fracture. To understand susceptibility to these side effects, Surface et al. investigated the role of the gene ATRAID in mediating responses to N-BPs. Atraid-deficient mice had weaker bones and did not respond to N-BP treatment in models of osteoporosis, and patients with coding variants in ATRAID taking N-BPs presented with atypical fractures and osteonecrosis of the jaw. The authors determined that ATRAID is necessary for inhibition of osteoclast function by N-BPs. Results suggest that it may be prudent to screen patients for variants in ATRAID to avoid N-BP side effects.

View Full Text

Stay Connected to Science Translational Medicine